US Managing Common Illness Consumer Report 2026
The market for cold, cough, flu and allergy (CCFA) treatments is complex, shaped by confident consumers, a paradox of choice and a growing interest in natural remedies.
Trusted by leading global brands
Collapse All
-
EXECUTIVE SUMMARY
- What you need to know
- Outlook for the cold, cough, flu and allergy market
- Opportunities
- Use the retail experience to educate consumers and reduce product overwhelm
- Multi-symptom relief is a cost-of-entry
- Leverage holistic interests to build usage occasions and trust
- Graph 1: select non-medicinal interventions to managing common illness, 2026
-
THE MARKET
- Snapshot – market size and forecast for cold, cough, flu and allergy remedies
- Consumers and the economic outlook
- US economic snapshot
- Tariffs on pharmaceutical ingredients
- Additionally, the battle over oral phenelphrine is still in limbo
- Rx brands enter the OTC space
- Market size and forecast of cold, cough, flu and allergy remedies
- Graph 2: value fan chart, total forecasted sales of cold, cough, flu and allergy remedies, 2019-30
- Retail sales and forecast of cold, cough, flu and allergy remedies at current prices
- Retail sales and forecast of cold, cough, flu and allergy remedies at inflation-adjusted prices
- Market segmentation of cold, cough flu and allergy remedies
- Graph 3: total retail sales and forecast of cold, cough, flu and allergy remedies, by segment, at current prices, 2019-30
- Sales of cold, cough and flu remedies by brand/company
- Sales of allergy remedies by brand/company
-
THE CONSUMER
- Nearly one third remain unvaccinated
- Graph 4: vaccination status, 2026
- CDC efforts to increase vaccination levels are underway, but more work is needed
- Understand social influences on younger consumers’ health decisions
- Capitalize on the self-diagnosis era to empower confident consumers
- Graph 5: confidence in ability to differentiate illnesses – NET, 2026
- Address moderate symptoms with symptom-shortening solutions
- Graph 6: severity of illness, 2026
- Shift from :severity of symptoms” to “first symptoms” messaging
- Multi-benefit and multi-system are critical to compete
- Graph 7: first CCFA solution, 2026
- Multi-benefit solutions can still be used to help niche audiences
- Shift messaging away from powering through illness
- Look beyond format to aesthetics and sensory upgrades
- Graph 8: total percentage of decongestive, cough, cold and flu relief product launched, by format type, 2021-25
- Renovate and modernize with format and packaging design
- Fast-acting, multi-symptom relief continues to be a non-negotiable for CCFA products
- Graph 9: most important factors of CCFA products, 2026
- Younger shoppers seek personalized formulas, while older shoppers seek familiarity
- Graph 10: most important factors of CCFA products, 2026
- Elevate certain claims to attract different audiences
- A move toward proactive health management opens up new market opportunities
- Graph 11: non-medicinal interventions to managing common illness, 2026
- Create connections between systems for a holistic approach
- Holistic health solutions may become synonymous with natural
- Graph 12: non-medicinal interventions to managing common illness by trust in natural solutions, 2026
- Enhance natural solutions with added “holistic” benefits
-
APPENDIX
- Market definition
- The market
- Forecast methodology
- Forecast methodology – fan chart
- Market forecast and prediction intervals for cold, cough flu and allergy remedies
- The consumer
- Consumer research questions
- Crosstab 1
- Graph 13: vaccine status and confidence in differentiating symptoms, 2026
- Crosstab 2
- Graph 14: vaccine status by non-medicinal common illness management, 2026
- Crosstab 3
- Graph 15: vaccine status by attitudes and behaviors around managing common illness, 2026
- Crosstab 4
- Graph 16: confidence in differentiating illness by attitudes and behaviors around managing common illness, 2026
- Consumer research methodology
- US generation groups
- Other data source methodologies
- Mintel Spark
- Abbreviations
The market for cold, cough, flu and allergy (CCFA) treatments is complex, shaped by confident consumers, a paradox of choice and a growing interest in natural remedies. Projections indicate the market will reach $12.3 billion by 2030; however, this growth is met with evolving consumer behaviors that present both challenges and opportunities for brands.
One of the biggest trends is a growing consumer preference for holistic health solutions. Many are turning to non-medicinal interventions, which diverts spending from traditional OTC medications. This shift poses a threat to brands that fail to adapt, but it also creates an opportunity for those that can innovate with homeopathic-focused products.
The pivot toward self-diagnosis is happening alongside high health confidence. A remarkable 87% of consumers believe they can self-diagnose common illnesses like a cold, flu or allergies. However, this confidence often wavers at the shelf. Despite feeling equipped to identify their ailments, 27% of these same consumers report feeling overwhelmed and confused by the vast array of available treatments. This sense of confusion is likely to increase as regulatory shifts continue to transition more products from prescription-only to over-the-counter status, further broadening the options available.
This Report Looks at the Following Areas:
- Ability to recognize symptoms
- Trends in vaccination and preventative care
- Shifts in consumer confidence for illness differentiation
- Purchase factors affecting consumer behavior
- Market dynamics and sales forecasts for CCFA remedies
Market Definitions
This Report covers remedies that can be purchased over-the-counter without a prescription to relieve symptoms of colds, flu, allergies, sore throat, coughs and congestion.
Cold, flu, and sinus remedies including tablets, capsules, liquids, powders and hot drinks for treating cold/flu and/or nasal and chest congestion.
- Nasal remedies include nasal strips and aspirators.
Cough/throat remedies include cough/sore throat drops; cough syrups/sore throat liquid medicine.
Allergy remedies include tablets, capsules, liquids, powders and nasal sprays.
£ 3,695 excl. Tax
Secure direct checkout
Instant PDF download
Portal access included
Need help deciding?
Get in touch
Trusted by global industry leaders
We have such a great working relationship with Mintel on lots of different levels. As an insight partner, they have helped us to develop our business planning in specific categories as well as supporting our creative process but they’ve also been super helpful with facilitating our events in their inspirational offices near St Paul’s.
They’re an innovative company, with a client-focused team that always delivers.
Abby Carvosso, Group Managing Director, Bauer Media Group
Mintel is really good for getting a handle on a particular category quickly. If we are working on a new business pitch in an area we don’t have much experience in, it’s a brilliant way to get up to speed with what’s going on, what’s changing and what the key trends are in any category.
It’s very rare now that anyone will plough through a 200-page report – that’s why the summaries are really useful. We know they are backed up by a lot of detail, so if you need to go into something in more depth you know the information will be all there for you.
Pauline Robson, Managing Partner, Mediacom
We’ve found it so useful working more closely with Mintel. They helped support our recent flagship event for our top suppliers by providing a really unique viewpoint on the future of online retailing.
Nick Carroll from their Retail Team was also an excellent panelist, sharing useful and actionable consumer insights. We definitely look forward to working with Mintel again on future projects.
Zac Steele, E-Commerce Trading Development Manager, Waitrose & Partners
One of the biggest challenges we face is the need to get smart on a business or category real quick.
We are talking to clients who live and breathe their category every day and the expectation is that we will be able to get caught up very quickly, and bring the thinking that can help them.
We need to do that often in a matter of days, so it’s not a small ask. Mintel gives us a very articulate view of category conditions and does so at the speed we need it.
Jeff White, Business Development Director, Deutsch
At Jackman, we believe that powerful strategies are based on human insight. Mintel’s leading-edge reports and insights into consumer attitudes and behaviors are an important input as we develop and execute strategy.
Alana Gavin, VP Research and Insights, Jackman
